Article Figures & Data
Figures
- Figure 1.
Overall survival of patients receiving TILs with the chemotherapy preparative regimen alone (no TBI) or plus 2 or 12 Gy TBI.
- Figure 2.
Overall survival of patients receiving cell transfer based on prior treatment received.
- Figure 3.
Mean telomere length, the number of CD27+CD8+ cells, and the percentage persistence of the infused cells in peripheral blood at 1 month after cell infusion are significantly different in objective responders (CR + PR) compared with nonresponders (all P2 < 0.001). anti-CTLA4, a-CTLA4. Data updated as of January 1, 2011.
Tables
- Table 1.
Cell transfer therapy
Treatment n (%) of patients (duration in mo) OR (%) Total PR CR No TBI 43 16 (37) 5 (12) 21 (49) 84, 36, 29, 28, 14, 12, 11, 7, 7, 7, 7, 4, 4, 2, 2, 2 82+, 81+, 79+, 78+, 64+ 200 TBI 25 8 (32) 5 (20) 13 (52) 14, 9, 6, 6, 5, 4, 3, 3 68+, 64+, 60+, 57+, 54+ 1,200 TBI 25 8 (32) 10 (40) 18 (72) 21, 13, 7, 6, 6, 5, 3, 2 48+, 45+, 44+, 44+, 39+, 38+, 38+, 38+, 37+, 19 Total 93 32 (34) 20 (22) 52 (56) NOTE: Data updated as of August 1, 2010.
- Table 2.
Patient and treatment characteristics
Number of patients P2 CR PR NR Total CR vs. (PR + NR) (CR + PR) vs. NR Total 20 32 41 93 Patients Sex Male 13 20 29 62 1.0 <0.51 Female 7 12 12 31 Age 16–30 3 5 4 12 0.84 0.79 31–45 7 11 14 32 46–60 10 16 21 47 61–75 0 0 2 2 HLA A2 15 28 32 75 0.53 0.61 Non-A2 5 4 9 18 Stage M1a 3 4 6 13 0.55 0.56 M1b 3 4 1 8 M1c 14 24 34 72 Treatments TBI, Gy 0 5 16 22 43 0.007 0.08 2 5 8 12 25 12 10 8 7 25 Cells (×10−10) <3 4 5 10 19 3.1–5.0 3 4 12 19 5.1–7.0 7 12 7 26 7.1–9.0 2 4 4 10 >9 4 7 8 19 Mean ± SEM 6.5 ± 0.7 6.1 ± 0.5 5.5 ± 0.6 0.25 0.07 % CD3CD8+ 86 ± 2 79 ± 4 74 ± 4 0.59 0.14 % CD3CD4+ 10 ± 2 20 ± 4 24 ± 4 0.30 0.15 Telomere length, kb 6.7 ± 0.3 6.4 ± 0.2 5.1 ± 0.2 0.006 <0.001 CD8+CD27+ cells (×10−10) 2.0 ± 0.3 1.5 ± 0.2 0.8 ± 0.1 0.001 <0.001 Persistence at 1 mo (%) 30.2 ± 5.5 28 ± 5.9 10.5 ± 3.5 0.003 <0.001 IL-2 doses <5 1 3 1 5 5–8 15 22 19 56 9–11 4 7 21 32 Mean ± SEM 7.1 ± 0.4 7.7 ± 0.5 8.8 ± 0.4 0.11 0.003 Abbreviations: M1a, skin, subcutaneous, or nodal metastases; M1b, lung; M1c all other visceral sites or elevated LDH levels.
- Table 3.
Impact of prior treatment on response to cell transfer therapy using selected TILs
n (%)a ORb Total CR PR All patients 93 20 (22) 32 (34) 52 (56) Prior treatment None 5 (5) 2 (40) 1 (20) 3 (60) IL-2 77 (83) 14 (18) 28 (36) 42 (54) Chemotherapy 40 (43) 7 (18) 16 (40) 23 (58) IFN 52 (56) 11 (21) 17 (33) 28 (54) Anti-CTLA4 11 (12) 5 (45) 2 (18) 7 (64) IL-2+ chemotherapy 37 (40) 6 (16) 16 (43) 22 (59) IL-2+ anti-CTLA4 8 (9) 3 (38) 1 (13) 4 (50) IL-2+ anti-CTLA4+ chemotherapy 6 (7) 2 (33) 1 (17) 3 (50)
CCR Translation for This Article
This article refers to the following CCR Translation:
Getting Personal with Melanoma
Helen HeslopSupplementary Data
Supplementary Figures S1-S2; Supplementary Tables S1-S2.
Files in this Data Supplement:
- Supplementary Data - Supplementary Figures S1-S2; Supplementary Tables S1-S2.
Volume 17, Issue 13
